

Table S1. Unadjusted and adjusted hazard ratios for OS in 433 patients with known *RASRAS* and *BRAFBR AF*^{V600E} mutational status*

Variable	Unadjusted		Adjusted	
	HR (CI 95%)	<i>P</i>	HR (CI 95%)	<i>P</i>
<i>BRAF</i> ^{V600E} mutated vs <i>BRAFBR AF</i> wild-type	1.36 (0.95 to 1.94)	.092	1.06 (0.66 to 1.70)	.811
Age at <u>first injectionstart of ICI therapy</u>	1.01 (1.00 to 1.03)	.027	1.01 (1.00 to 1.03)	.094
Female vs male	0.88 (0.63 to 1.25)	.485	0.78 (0.54 to 1.12)	.180
Left-sided vs right-sided	1.24 (0.87 to 1.77)	.230	1.32 (0.89 to 1.97)	.165
Anti-PD1 + anti-CL4 vs anti-PD1	0.36 (0.24 to 0.56)	<.001	0.38 (0.24 to 0.61)	<.001
<i>KRAS/NRAS</i> mutated vs <i>RASRAS</i> wild-type	0.68 (0.46 to 0.99)	.046	0.75 (0.48 to 1.17)	.202
ECOG performance score		<.001		<.001
1 vs 0	2.01 (1.39 to 2.90)		2.18 (1.45 to 3.25)	
2 vs 0	4.43 (2.39 to 8.21)		4.01 (2.00 to 8.04)	
≥ 2 metastatic sites vs 1 metastatic site	1.28 (0.90 to 1.82)	.177	1.11 (0.77 to 1.61)	.577
≥ 1 prior treatment line vs no prior treatment line	1.98 (1.19 to 3.30)	.008	2.44 (1.41 to 4.20)	.001
Primary tumor surgery vs no primary tumor surgery	0.66 (0.38 to 1.15)	.143	0.62 (0.34 to 1.12)	.112

* Only patients with all the data variables available CI = confidence Interval; ECOG = Eastern Oncology Cooperative Group; HR = hazard ratio.

Table S2. Unadjusted and adjusted hazard ratios for OS in 231 patients with determined Lynch syndrome and sporadic status*

Variable	Unadjusted		Adjusted	
	HR (CI 95%)	<i>P</i>	HR (CI 95%)	<i>P</i>
Lynch vs sporadic	0.38 (0.21 to 0.69)	.001	0.56 (0.25 to 1.22)	.143
Age at first injection <u>start of ICI therapy</u>	1.03 (1.01 to 1.05)	.002	1.01 (0.99 to 1.03)	.421
Female vs male	1.39 (0.82 to 2.38)	.225		
Left-sided vs right-sided	1.02 (0.55 to 1.87)	.954		
Dual therapy vs monotherapy	0.37 (0.20 to 0.69)	.002	0.43 (0.22 to 0.84)	.014
<u>RASRAS</u> mutated vs <u>RASRAS</u> wild-type	0.41 (0.19 to 0.87)	.021	0.74 (0.30 to 1.82)	.514
ECOG performance score		<.001		.003
1 vs 0	2.42 (1.30 to 4.51)		2.57 (1.29 to 5.08)	
2 vs 0	6.82 (2.59 to 18.0)		5.26 (1.83 to 15.1)	

≥2 metastatic sites vs 1 metastatic site	0.96 (0.56 to 1.65)	.878		
≥1 prior treatment line vs no prior treatment line	1.18 (0.59 to 2.35)	.634		
Primary tumor surgery vs no primary tumor surgery	0.50 (0.23 to 1.11)	.089	0.47 (0.20 to 1.10)	.081

* Only patients with all the data variables available. CI = confidence Interval; ECOG = Eastern Oncology Cooperative Group; HR = hazard ratio.